The Employee Profile in China Pharma R&D
Source: Appliedclinicaltrialsonline.com
Pharmaceutical companies are currently targeting the emerging markets of China and Africa for their future expansion, with the highest investment - USD 5.32 billion - just in China alone. Around 29 plants with a combination of manufacturing, production units and research & development centers are scheduled to open through the 2015 to 2022 period across regions. In addition to new facilities, approximately five brownfield expansions and nine closures are also scheduled within the same period. Figure 1 shows the various expansions vs. closures regionally planned by the top 10 big pharma companies
Related News
View allBeroe introduces on-demand geopolitical risk analysis through PRISM enabling C-Suite to protect against ongoing supply chain disruptions
PR Newswire
Beroe Inc · 6 March 2024
Read More
Beroe and Upply Combine their Expertise to Revolutionize Logistics Solutions
PR Newswire
Beroe Inc · 16 January 2024
Read More
Agilent Technologies selects Beroe to Elevate Procurement Excellence
Beroe Inc.
Beroe Inc · 26 October 2023
Read More